Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.
Graziano
R F
RF
Medarex Inc., Annandale, NJ 08801, USA. rgrazian@injersey.com
Goldstein
J
J
Sundarapandiyan
K
K
Somasundaram
C
C
Keler
T
T
Deo
Y M
YM
D018033:Antibodies, Bispecific / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D000920:Antibody-Dependent Cell Cytotoxicity; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000235:genetics / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism*; D005822:Genetic Vectors; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology; D020890:Neuregulin-1; D017452:Receptors, IgG / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D018033:Antibodies, Bispecific; D002352:Carrier Proteins; D006023:Glycoproteins; D020890:Neuregulin-1; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins; D018799:Intercellular Adhesion Molecule-1; C087230:heregulin beta1; D004815:Epidermal Growth Factor; D007371:Interferon-gamma; D066246:ErbB Receptors